Retrospective analysis identifies alkaline phosphatase-to-albumin ratio predicting survival in metastatic hormone-sensitive prostate cancer, suggesting its use as a biomarker.
Background: Metastatic hormone-sensitive prostate cancer (mHSPC) requires accessible biomarkers for better prognostication. This study investigated the prognostic value of the alkaline phosphatase-to-albumin ratio (APAR) in mHSPC survival risk stratification.Methods: We retrospectively analyzed 128 mHSPC patients. A cut-off of 2.92 for APAR was determined via ROC analysis. Overall survival (OS) was assessed using Kaplan–Meier methods and multivariable Cox regression adjusting for standard prognostic factors, including tumor volume and Gleason score.Results: Patients with APAR ≥2.92 had significantly shorter OS compared to those with APAR
No takes yet. Share an insight, caveat, or question.
Özalp et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: